Relapsing Fever is marked by recurring episodes of high fever that are accompanied by chills, headache and myalgias. Our partners are able to make sound decisions in their vaccine development and therapy by virtue of us offering quality services.
Overview of Relapsing Fever
Relapsing fever is an illness caused by bacteria belonging to the Borrelia genus that is spread through lice or tick bites; it is classified as a vector-borne disease. Due to its intrinsic characteristics and the issue of finding effective interventions, this infection is both exceptionally complicated and fascinating - a viewpoint first formulated by ancient Greeks centuries ago.
Often, it has been observed that diseases like relapsing fever occur in parts of Africa and Asia, as well as some regions of Europe and America, where the standard of public health is considerably low. These are also areas where the presence of suitable vectors and reservoirs is almost non-existent, resulting in the disease being geographically limited. Furthermore, diagnosis and therapeutics are difficult due to over 30 species in the Borrelia genus that are pathogenic to humans.
Fig.1 Global distribution of RF Borrelia. (Lopez J., et al., 2021)
Vaccine Development for Relapsing Fever
The creation of a vaccine for relapsing fever poses a considerable challenge primarily because of the ability of Borrelia species to undergo antigenic variation. This attribute enhances the pathogen's capacity to evade the immune system by altering surface proteins which makes it hard for the immune system to detect and eliminate the pathogen.
Louse-Borne Relapsing Fever Vaccine
Relapsing fever that is transmitted by louse, characterized by Borrelia recurrentis, is associated with violent epidemics in underdeveloped areas. In this consideration, the development of a vaccine for this type would mainly directed towards the antigens presented by Breametric Rationale.
Tick-Borne Relapsing Fever Vaccine
Tick-borne relapsing fever applies to Borrelias other than B. hermsii, for example, B. miyamotoi. The vaccine development for this group is somewhat more complicated as it requires dealing with the multitude of specificities possessed by the various species.
Therapeutics Development for Relapsing Fever
In cases of relapsing fever, antibiotics including tetracyclines are normally administered as a first line treatment. But the risks of relapse and the development of antibiotic resistant organisms indicate that there is a need for new effective antimicrobial agents.
Development of new therapeutic agents aims at utilizing the target biology of Borrelia species including the metabolic activity and immune evasive properties they exhibit. Some of such agents could be small molecules, monoclonal antibodies or other biologics that can be effective in treating the infection. To know more about our companys solutions, please click on the links below.
Our Services
Our company is determined in the advancement of vaccines and therapies for relapsing fever. For us the whole aspect of development, from a concept to preclinical trials, is wide-ranging and offering services in such is rather inclusive.
- Immunocompetent Inbred Mice Models
- SCID BEIGE Mice Models
- Clodronate Liposome-Induced Phagocyte Depletion Models
- Non-Primate Animal Models
Our preclinical studies enable the formulation of proficient vaccines and therapeutics. The joint endeavors with the academia and the industrial partners provide additional depth to our research. Please do not hesitate to contact us if you want any of our services or you are interested in working with us.
References
- Lopez Job, Joppe W. Hovius, and Sven Bergstrom. "Pathogenesis of relapsing fever." Current issues in molecular biology 42.1 (2021): 519-550.
- Barbour, Alan G., and Sheldon L. Kaplan. "Clinical features, diagnosis, and management of relapsing fever." UpToDate (2018).
All of our services and products are intended for preclinical research use
only and cannot be used to diagnose, treat or manage patients.
